(Q33397018)

26 July 2017

title

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study (English)

1 reference

26 July 2017

4

Nicola Fazio

1 reference

26 July 2017

Giovanni Paganelli

12

0 references

author name string

Lisa Bodei

1

1 reference

26 July 2017

Marta Cremonesi

2

1 reference

26 July 2017

Chiara M Grana

3

1 reference

26 July 2017

Simona Iodice

5

1 reference

26 July 2017

Silvia M Baio

6

1 reference

26 July 2017

Mirco Bartolomei

7

1 reference

26 July 2017

Dario Lombardo

8

1 reference

26 July 2017

Mahila E Ferrari

9

1 reference

26 July 2017

Maddalena Sansovini

10

1 reference

26 July 2017

Marco Chinol

11

1 reference

26 July 2017

publication date

3 September 2011

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

26 July 2017

published in

1 reference

26 July 2017

volume

38

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

2125-2135

1 reference

Gastroenteropancreatic neuroendocrine tumours

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Peptide receptor therapies in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Introduction to clinical radiation biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1902-1

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

21 January 2018

1 reference

12 December 2020

Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

Incorporating toxicity considerations into the design of two-stage phase II clinical trials

1 reference

12 December 2020

10.1007/S00259-011-1902-1

Identifiers

DOI

1 reference

26 July 2017

1 reference